Back to Browse Journals » Infection and Drug Resistance » Volume 4

Current treatment of choice for chronic hepatitis C infection

Authors Tareq Yasin, Thomas R Riley, Ian R Schreibman

Published Date January 2011 Volume 2011:4 Pages 11—18

DOI http://dx.doi.org/10.2147/IDR.S4827

Published 12 January 2011

Tareq Yasin, Thomas R Riley, Ian R Schreibman
Penn State Hershey Medical Center and College of Medicine, Pennsylvania, USA

Abstract: More than three million Americans have chronic hepatitis C infection, and the disease remains one of the most common blood-borne infections in the US. Treatment is focused on the chronic form of the disease, because the acute one tends to be self-limiting. In this article, we review the recent literature regarding the most effective therapy against hepatitis C infection, to confirm the current treatment of choice for the disease. We conclude that combination therapy with pegylated interferon and ribavirin remains the initial treatment of choice. New research focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early data that appear to be promising.

Keywords: hepatitis C virus, infection, chronic, treatment, pegylated interferon, ribavirin

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

Chaparro-Rojas F, Mullane KM

Infection and Drug Resistance 2013, 6:41-53

Published Date: 28 June 2013

Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity

Yin PH, Wang Y, Qiu YY, Hou LL, Liu X, Qin JM, Duan YR, Liu PF, Qiu M, Li Q

International Journal of Nanomedicine 2012, 7:3961-3969

Published Date: 27 July 2012

Resistance to antimicrobial drugs in Ghana

Newman MJ, Frimpong E, Donkor ES, Opintan JA, Asamoah-Adu A

Infection and Drug Resistance 2011, 4:215-220

Published Date: 21 December 2011

Evaluation of intralesional propranolol for periocular capillary hemangioma

Awadein A, Fakhry MA

Clinical Ophthalmology 2011, 5:1135-1140

Published Date: 15 August 2011

Treatment of drug-resistant tuberculosis

Pinto LM, Menzies D

Infection and Drug Resistance 2011, 4:129-135

Published Date: 21 July 2011

Profound thrombocytopenia after primary exposure to eptifibatide

Nicholas B Norgard, Brian T Badgley

Drug, Healthcare and Patient Safety 2010, 2:163-167

Published Date: 21 September 2010

Potential antidiabetic and antioxidant activities of Morus indica and Asystasia gangetica in alloxan-induced diabetes mellitus

R Pradeep Kumar, D Sujatha, TS Mohamed Saleem, C Madhusudhana Chetty, D Ranganayakulu

Journal of Experimental Pharmacology 2010, 2:29-36

Published Date: 10 February 2010

Dedifferentiated chondrosarcoma arising in fibrous dysplasia: A case report and review of the current literature

Nicole MD Riddle, Hideko Yamauchi, Jamie T Caracciolo, David Johnson, et al.

Pathology and Laboratory Medicine International 2009, 1:1-6

Published Date: 8 June 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009